BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

...Newton Biocapital. DeuterOncology has a sublicense to worldwide rights outside greater China for all the compounds Octimet Oncology N.V....
BioCentury | Feb 11, 2021
Finance

Belgium’s V-Bio looking for bigger bets in and out of its home country with

...firm and will invest alongside Takke and Willem Broekaert. Margetson is CEO of cancer company Octimet Oncology N.V....
BioCentury | Oct 20, 2017
Emerging Company Profile

One-upping c-MET

...a plethora of c-MET inhibitors in the clinic for cancer and two on the market, Octimet Oncology N.V....
...Novartis declined to comment, and AZ did not respond to request for comment. COMPANY PROFILE Octimet Oncology N.V....
...NYSE:JNJ), New Brunswick, N.J. Merck KGaA (Xetra:MRK), Darmstadt, Germany Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Octimet Oncology N.V....
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

...cell gene therapy Gene/Cell therapy; Hematology; Endocrine/ Metabolic Phase I/II V-Bio Venture Fund I (2015) Octimet Oncology N.V....
BioCentury | Apr 7, 2017
Finance

Fast-growing evergreen

...S.A. , as well as cancer companies iTeos Therapeutics S.A. , eTheRNA immunotherapies N.V. and Octimet Oncology N.V. Virginia...
BioCentury | Jan 21, 2017
Finance

Selective investment

...Investors in Octimet Oncology N.V. ’s series A round believe the selectivity of OMO-1 for its target, plus...
BioCentury | Jan 20, 2017
Financial News

Octimet Oncology completes venture financing

...On Jan. 19, cancer play Octimet Oncology N.V. (Beerse, Belgium) raised €11.3 million ($12 million) in a series...
...Ventures and Fund+. Droia Oncology Ventures and Omnes Capital also participated. Octimet Oncology N.V. , Beerse, Belgium Alicia Parker Octimet Oncology...
BioCentury | Jan 19, 2017
Financial News

Octimet raises EUR 11.3M in series A

...Cancer play Octimet Oncology N.V. (Beerse, Belgium) raised EUR 11.3 million ($12 million) in a series A financing...
...J&J's scientific, technical and business capabilities (see BioCentury Extra, March 16, 2016) . Becky Simon Johnson & Johnson Octimet Oncology...
BioCentury | Jan 6, 2017
Company News

J&J reveals spate of partnerships

...will join the incubator, along with immuno-oncology company eTheRNA N.V. (Brussels, Belgium) and cancer play Octimet Oncology...
Items per page:
1 - 9 of 9
BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

...Newton Biocapital. DeuterOncology has a sublicense to worldwide rights outside greater China for all the compounds Octimet Oncology N.V....
BioCentury | Feb 11, 2021
Finance

Belgium’s V-Bio looking for bigger bets in and out of its home country with

...firm and will invest alongside Takke and Willem Broekaert. Margetson is CEO of cancer company Octimet Oncology N.V....
BioCentury | Oct 20, 2017
Emerging Company Profile

One-upping c-MET

...a plethora of c-MET inhibitors in the clinic for cancer and two on the market, Octimet Oncology N.V....
...Novartis declined to comment, and AZ did not respond to request for comment. COMPANY PROFILE Octimet Oncology N.V....
...NYSE:JNJ), New Brunswick, N.J. Merck KGaA (Xetra:MRK), Darmstadt, Germany Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Octimet Oncology N.V....
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

...cell gene therapy Gene/Cell therapy; Hematology; Endocrine/ Metabolic Phase I/II V-Bio Venture Fund I (2015) Octimet Oncology N.V....
BioCentury | Apr 7, 2017
Finance

Fast-growing evergreen

...S.A. , as well as cancer companies iTeos Therapeutics S.A. , eTheRNA immunotherapies N.V. and Octimet Oncology N.V. Virginia...
BioCentury | Jan 21, 2017
Finance

Selective investment

...Investors in Octimet Oncology N.V. ’s series A round believe the selectivity of OMO-1 for its target, plus...
BioCentury | Jan 20, 2017
Financial News

Octimet Oncology completes venture financing

...On Jan. 19, cancer play Octimet Oncology N.V. (Beerse, Belgium) raised €11.3 million ($12 million) in a series...
...Ventures and Fund+. Droia Oncology Ventures and Omnes Capital also participated. Octimet Oncology N.V. , Beerse, Belgium Alicia Parker Octimet Oncology...
BioCentury | Jan 19, 2017
Financial News

Octimet raises EUR 11.3M in series A

...Cancer play Octimet Oncology N.V. (Beerse, Belgium) raised EUR 11.3 million ($12 million) in a series A financing...
...J&J's scientific, technical and business capabilities (see BioCentury Extra, March 16, 2016) . Becky Simon Johnson & Johnson Octimet Oncology...
BioCentury | Jan 6, 2017
Company News

J&J reveals spate of partnerships

...will join the incubator, along with immuno-oncology company eTheRNA N.V. (Brussels, Belgium) and cancer play Octimet Oncology...
Items per page:
1 - 9 of 9